SPRY position history
The shares of Ars Pharmaceuticals (SPRY) that DAFNA Capital Management LLC reported in each quarter’s 13F.
Shares held by quarter
New Add Reduce Exit
- 2023 Q4: 311,169 shares, $1.7M, 0.41% of portfolio, New
- 2024 Q1: 239,194 shares, $2.4M, 0.56% of portfolio, Reduce −23.1%
- 2024 Q2: 239,194 shares, $2M, 0.49% of portfolio
- 2024 Q3: 148,294 shares, $2.2M, 0.51% of portfolio, Reduce −38.0%
- 2024 Q4: 88,790 shares, $937K, 0.24% of portfolio, Reduce −40.1%
- 2025 Q1: 95,290 shares, $1.2M, 0.34% of portfolio, Add +7.3%
- 2025 Q2: not held, Exit
- 2025 Q3: 140,500 shares, $1.4M, 0.35% of portfolio, New
- 2025 Q4: 190,065 shares, $2.2M, 0.51% of portfolio, Add +35.3%
- 2026 Q1: 139,285 shares, $1.1M, 0.25% of portfolio, Reduce −26.7%
- 2026 Q2: 164,285 shares, $1.3M, 0.25% of portfolio, Add +17.9%
| Holdings date | Value | % of holdings | Shares | Filing date | All 13F holders |
|---|